Health Care · Pharmaceutical Preparations

NKTX Nkarta, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 178740069 filings
Russell 2000

NKTX at a glance

Nkarta, Inc. (NKTX, SEC CIK 1787400) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as June 22, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Nkarta, Inc. (NKTX) reported revenue of $0 and a net loss of $104.1 million. Diluted EPS was -$1.41.
  • As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Nkarta, Inc. (NKTX) shares worth $53.0 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by HASTINGS PAUL J on June 18, 2026 of 1,776 shares at $2.71 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$0
10-K XBRL
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
25 funds
$53.0M · +0 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 7.01 · Item 8.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $0, with no product sales since inception
  • Operating margin not applicable, net loss $(33.3) million vs $(21.7) million YoY
  • NKX019 R&D spending $11.4 million, up from $4.3 million YoY
  • Cash, restricted cash and investments $216.0 million as of September 30, 2026
  • Operating cash outflow $78.3 million, up from $67.1 million YoY; funding sufficient for at least 12 months

Risk Factors

  • Losses $101.5 million, accumulated deficit $749.8 million as of September 30, 2026
  • Cash, restricted cash and investments $216.0 million, additional financing needed for pivotal trials
  • FDA-agreed amendments enabled outpatient dosing and re-dosing, increasing safety-monitoring and cumulative-toxicity exposure
  • Ntrust-1 and Ntrust-2 enrollment challenges from competition for autoimmune trial sites, investigators and patients
  • Miltenyi CliniMACS Plus system and reagents remain sole-source manufacturing inputs, with four-to-six-month reagent expiration windows

AI summary of the NKTX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • NKX019 initial clinical data released for myositis and systemic sclerosis from the Ntrust trial program
  • Data presented at ACR Convergence 2026, providing an external clinical validation forum

Item 8.01: Other Events

  • Preliminary NKX019 efficacy signal in myositis: 5/6 patients, 83%, achieved moderate or major responses at 4 billion cells per dose
  • Systemic sclerosis results stronger at 4 billion cells: 6/7 patients, 86%, reached rCRISS-25 response or greater by Day 90

Item EX-99.1: Item EX-99.1

  • Preliminary NKX019 data support clinical activity in refractory autoimmune disease, strengthening Nkarta’s lead program ahead of regulatory discussions
  • Myositis: 5/6 patients achieved moderate or major responses at 4 billion cells per dose, including one sustained TIS 90 response at six months

Item EX-99.2: Item EX-99.2

  • NKX019 4B-dose cohort showed 5/6 myositis patients with moderate-to-major TIS responses after ≥3 months
  • Systemic sclerosis results: 6/7 achieved rCRISS-25 and 5/7 achieved rCRISS-50 by Day 90
Filed Nov 6, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Webcast scheduled November 9, 2026 at 8:00 a.m. Eastern Time
  • Initial clinical data from NKX019’s Ntrust program in myositis and systemic sclerosis

Item EX-99.1: Item EX-99.1

  • Webcast scheduled November 9, 2026 at 8:00 a.m. ET to present initial NKX019 clinical data at ACR Convergence 2026
  • Data cover Ntrust trials in myositis and systemic sclerosis, creating a near-term clinical catalyst for NKTX shares
Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for the quarter ended September 30, 2026
  • Full operating and financial details available in Exhibit 99.1, the company’s earnings press release

Item EX-99.1: Item EX-99.1

  • Q3 2026 net loss $33.3M, or $0.45 per share, versus $21.7M, or $0.29, in Q3 2025
  • R&D spending rose to $29.5M from $20.2M, reflecting accelerated NKX019 clinical development

AI summaries of NKTX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for NKTX

Don't miss the next NKTX filing

  • Alerts as it files. A push when NKTX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut NKTX, by share count.
  • Ask anything. An AI agent that reads every NKTX filing and answers with sources.

NKTX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
HASTINGS PAUL JSellJun 18, 2026$2.71
Behbahani AliAJun 10, 2026-
PATTERSON LEONE DAJun 10, 2026-
Scheiner ZacharyAJun 10, 2026-
Vratsanos GeorgeAJun 10, 2026-
RA CAPITAL MANAGEMENT, L.P.AJun 10, 2026-
Thedinga AngelaAJun 10, 2026-
George SimeonAJun 10, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$0$0
Operating Income--$128.2M-$122.0M
Net Income-$117.5M-$108.8M-$104.1M
Balance Sheet
Total Assets-$501.2M$404.2M
Equity-$408.0M$312.3M
ROE--26.7%-33.3%
Per Share
EPS$-2.40$-1.60$-1.41
Cash Flow
Operating CF-$86.2M-$99.7M-$88.7M
CapEx$28.1M$4.4M$1.2M

Source: XBRL data in Nkarta, Inc. (NKTX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate NKTX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
NKTX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202625$53.0M
Q2 202625$57.6M
Q1 202624$36.4M
Q4 202524$29.1M
Q3 202522$35.8M
Q2 202522$28.0M
Q1 202520$27.4M
Q4 202417$27.7M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 179 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

NKTX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 9, 2026Analysis-
8-KNov 6, 2026Analysis-
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
10-QAug 10, 2026Analysis
8-KAug 10, 2026Analysis-
4Jun 22, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
8-KJun 11, 2026Analysis-
4Jun 11, 2026--
8-KMay 12, 2026Analysis
10-QMay 12, 2026Analysis
8-KMar 26, 2026--
8-KMar 25, 2026--
10-KMar 25, 2026-
4Jan 20, 2026-
4Jan 20, 2026-
4Jan 8, 2026-
4Jan 8, 2026-

Related Health Care companies

All Health Care →

NKTX SEC filings: frequently asked questions

Which institutions hold NKTX stock?

As of September 30, 2026, the largest Nkarta, Inc. (NKTX) holders among the 13F filers tracked by SignalX were BlackRock ($17.9 million), Vanguard Capital Management LLC ($6.2 million), Citadel Advisors LLC ($4.5 million), Two Sigma Investments ($4.4 million), AQR Capital Management ($3.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was NKTX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Nkarta, Inc. (NKTX) reported revenue of $0 and a net loss of $104.1 million. Diluted EPS was -$1.41. The figures come from the XBRL data in the 10-K.

What did NKTX report in its latest 8-K?

Nkarta, Inc. (NKTX) filed an 8-K on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). NKX019 initial clinical data released for myositis and systemic sclerosis from the Ntrust trial program.

What are the latest NKTX SEC filings?

Nkarta, Inc. (NKTX) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on June 22, 2026.

What is NKTX's SEC CIK number?

Nkarta, Inc. (NKTX)'s SEC Central Index Key (CIK) is 1787400. EDGAR lists every NKTX filing under that number.

Ask anything about NKTX

The research agent reads NKTX's filings, financials, insider trades and 13F holders, then answers with sources.